Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
暂无分享,去创建一个
M. Ghielmini | L. Leibovici | M. Dreyling | L. Vidal | O. Shpilberg | A. Gafter-Gvili | A. Cohen | S. Hsu Schmitz
[1] Yana Zhang,et al. B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period , 2008, Leukemia & lymphoma.
[2] A. Berrebi,et al. Predictive Factors to Hypogammaglobulinemia and Non-Neutropenic Infection Complications after Rituximab/Chemotherapy Treatment , 2007 .
[3] G. Schwarzer,et al. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. , 2007, The Cochrane database of systematic reviews.
[4] G. Guyatt,et al. Systematic reviewers neglect bias that results from trials stopped early for benefit. , 2007, Journal of clinical epidemiology.
[5] R. Gascoyne,et al. Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: Results from the ECOG/CALGB intergroup E1496 trial , 2007 .
[6] M. Sydes,et al. Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.
[7] A. Stevens,et al. Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario. , 2007, Cancer treatment reviews.
[8] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] W. Hiddemann,et al. Clinical Trials and Observations , 2005 .
[10] Max Wolf,et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. , 2006, Blood.
[11] J. Shortt,et al. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma , 2006, Bone Marrow Transplantation.
[12] G. Rossi,et al. Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments , 2006, Leukemia & lymphoma.
[13] R. Gascoyne,et al. Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. , 2005 .
[14] Gordon H Guyatt,et al. Randomized trials stopped early for benefit: a systematic review. , 2005, JAMA.
[15] J. Hainsworth,et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] N. Mendenhall,et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. H. Lim,et al. Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia , 2005, Bone Marrow Transplantation.
[18] M. Ghielmini,et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. , 2004, Blood.
[19] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[20] K. Maclennan,et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial , 2003, The Lancet.
[21] E. Lanino,et al. Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy. , 2003, Journal of hematotherapy & stem cell research.
[22] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Parmar,et al. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.
[24] R. J. Hayes,et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.
[25] S. Horning. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. , 1993, Seminars in oncology.
[26] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.